BAY1211163

BAY1211163 is a soluble guanylate cyclase (sGC) activator developed by Bayer. It was investigated as an inhaled therapy for acute respiratory distress syndrome (ARDS), a severe lung condition characterized by fluid buildup in the lungs and difficulty breathing. The drug’s mechanism of action involves activating sGC, which increases cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and potential bronchodilation. Clinical development focused on determining the highest safe dose and evaluating safety and pharmacokinetics in patients with ARDS who require mechanical ventilation. As of the latest available information, development has been discontinued after phase 1 trials[1][2][5][7].